SCHEMBL155757

SCHEMBL155757

CCN1CCc2ccccc21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.70
MEN1 O00255 5/20 0.70
KMT2A Q03164 5/20 0.70
USP2 O75604 1/20 0.70
CDK4 P11802 1/20 0.70
ALOX15 P16050 1/20 0.70
CCND1 P24385 1/20 0.70
MAPT P10636 3/20 0.61
KDM4E B2RXH2 2/20 0.61
LMNA P02545 1/20 0.61
PTK2B Q14289 1/20 0.61
ESR2 Q92731 1/20 0.61
POLB P06746 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
HSD17B3 P37058 1/20 0.53
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
TRPM5 Q9NZQ8 1/20 0.49
TAAR1 Q96RJ0 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29877466 1.00 ALDH1A1 (0.70) ALDH1A1MEN1KMT2AUSP2CDK4
Ammonia Solution, Strong SCHEMBL11852266 0.98 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL30487785 0.88 ALDH1A1 (0.72) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL3233063 0.88 ALDH1A1 (0.72) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL12626929 0.86 ALDH1A1 (0.65) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL24721489 0.85 ALDH1A1 (0.63) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL24721277 0.85 ALDH1A1 (0.63) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL4935582 0.84 ALDH1A1 (0.78) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL12377760 0.83 ALDH1A1 (0.76) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL7940135 0.83 ALDH1A1 (1.00) ALDH1A1MEN1KMT2AUSP2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109678776-B Preparation method of 3-aryl succinimide compound 苏州大学 2020-07-14 CN claimed
CN-109678776-A The preparation method of 3- aryl succinimide class compound 苏州大学 2019-04-26 CN claimed
CN-1907253-A Composition comprising amino heterocyclic compound for hair dyeing and dyeing method SU JIANHUA (CN) 2007-02-07 CN claimed
CN-1253547-A 1,4-substituted cyclic amine derivatives EISAI CO LTD (JP) 2000-05-17 CN claimed
EP-4580621-A2 T-TYPE VOLTAGE-GATED CALCIUM CHANNEL POTENTIATORS The Broad Institute, Inc. (US) 2025-07-09 EP disclosed
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
CN-118382612-A Method for producing blocked isocyanate compound and method for producing isocyanate compound 旭化成株式会社 2024-07-23 CN disclosed
US-20240237518-A1 ORGANIC LIGHT EMITTING DEVICE LG CHEM, LTD. (KR) 2024-07-11 US disclosed
WO-2024050312-A2 T-TYPE VOLTAGE-GATED CALCIUM CHANNEL POTENTIATORS THE BROAD INSTITUTE, INC. (US) 2024-03-07 WO disclosed
WO-2024033479-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2024-02-15 WO disclosed
WO-2023244815-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
US-20230373919-A1 AT2R ANTAGONISTS AND USES THEREOF ELI LILLY AND COMPANY 2023-11-23 US disclosed
EP-1299393-A2 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THERAPEUTIC USE THEREOF Bristol-Myers Squibb Pharma Company (US) 2003-04-09 EP disclosed
US-6498183-B1 TREATMENT AND PROPHYLAXIS OF DISORDERS CAUSED BY HERPES VIRUSES, IN PARTICULAR HUMAN CYTOMEGALOVIRUS BAYER AKTIENGESELLSCHAFT (DE) 2002-12-24 US disclosed
WO-2002004455-A2 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THERAPEUTIC USE THEREOF ALBANY MOLECULAR RESEARCH, INC (US) 2002-01-17 WO disclosed
CN-1253547-A 1,4-substituted cyclic amine derivatives EISAI CO LTD (JP) 2000-05-17 CN disclosed
EP-0973813-A1 PRODUCTION OF HOMOCOPOLYMERS, CO-COPOLYMERS OR BLOCK COPOLYMERS FROM CYCLOOLEFINIC MONOMER UNITS BASF AKTIENGESELLSCHAFT (DE) 2000-01-26 EP disclosed
WO-1998045342-A1 PRODUCTION OF HOMOCOPOLYMERS, CO-COPOLYMERS OR BLOCK COPOLYMERS FROM CYCLOOLEFINIC MONOMER UNITS BASF AKTIENGESELLSCHAFT (DE) 1998-10-15 WO disclosed
US-5281659-A Polyester has copolymerized therein a nitrile substituted heterocyclic imide EASTMAN KODAK COMPANY (US) 1994-01-25 US disclosed
US-5194571-A Consisting of copolymer of electron rich aromatic moiety with polyester reacting groups; packaging EASTMAN KODAK COMPANY (US) 1993-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373919-A1 AT2R ANTAGONISTS AND USES THEREOF AGTR2, AGTR1, AVPR2 ALDH1A1 1261/4885MEN1 3920/4885KMT2A 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.